Strategies have therefore focussed on the use of nontoxic MGMT inactivators and it has been shown that O6-BeG and PaTrin-2, which very effectively inactivate MGMT in cells and tumours, improve the therapeutic effect of alkylating agents in a number of tumour models (Dolan and Pegg, 1997; Wedge et al, 1997; Middleton et al, 2002). The gene discussed is MGMT; the disease is neoplasm.